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Visual field loss and vision-related 
quality of life in the Italian Primary 
Open Angle Glaucoma Study
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Andreas Katsanos2, Francesco Oddone3, Valter Torri1, Robert N. Weinreb4 & Italian Study 
Group on QoL in Glaucoma*
The aim of this study was to examine the relationship between visual field (VF) loss, vision-related 
quality of life (QoL) and glaucoma-related symptoms in a large cohort of primary open angle glaucoma 
(POAG) patients. POAG patients with or without VF defects or “glaucoma suspect” patients were 
considered eligible. QoL was assessed using the validated versions of the 25-item National Eye Institute 
Visual Function Questionnaire (NEI-VFQ-25) and glaucoma-related symptoms were assessed using 
the Glaucoma Symptom Scale (GSS). Patients were classified as having VF damage in one eye (VFD-
1), both eyes (VFD-2), or neither eye (VFD-0). 3227 patients were enrolled and 2940 were eligible for 
the analysis. 13.4% of patients were classified in the VFD-0, 23.7% in the VFD-1, and 62.9% in the 
VFD-2 group. GSS visual symptoms domain (Func-4) and GSS non-visual symptoms domain (Symp-6) 
scores were similar for the VFD-0 and VFD-1 groups (p = 0.133 and p = 0.834 for Func-4 and Symp-
6, respectively). VFD-0 group had higher scores than VFD-2 both in Func-4 (p < 0.001) and Symp-6 
domains (p = 0.035). Regarding the NEI-VFQ-25, our data demonstrated that bilateral VF defects are 
associated with vision-related QoL deterioration, irrespective of visual acuity.
Glaucoma constitutes a major global cause or irreversible visual loss1. It is estimated that approximately 60 
million people worldwide have glaucoma and 8.4 million patients are bilaterally blind1. Of the many types of 
the disease, primary open angle glaucoma (POAG) is by far the commonest in populations of European ori-
gin2,3. As a chronic, progressive, vision-threatening disease, POAG can severely affect vision-related quality 
of life (QoL). Visual decline is a direct consequence of the glaucomatous process and can lead to limitations 
of daily functioning and loss of autonomy, thus causing deterioration of vision-related QoL and significant 
psychological burden4,5. In addition to the degradation of QoL due to the disease-related visual decline, 
factors such as adverse events of medication, cost of treatment, or even the distress elicited by the mere diag-
nosis of an irreversible, potentially blinding disorder can adversely affect the patient’s sense of well-being 
and QoL6–13.
The importance of preserving vision-related QoL at a sustainable cost has become increasingly recognized in 
glaucoma management14. Evidence has shown that patients with glaucoma often have problems with important 
daily activities such as walking15, driving16–18, or reading18, especially when perimetric damage is advanced or 
when both eyes are affected. Despite the recent interest in glaucoma-related QoL issues13,19–22, the relationship 
between vision-specific QoL and severity of visual field (VF) defects or number of eyes with perimetric loss 
warrants further exploration in sufficiently powered studies. In addition, the relationship between severity of VF 
damage or number of perimetrically affected eyes and glaucoma-related visual and non-visual symptoms needs 
to be better characterized in adequately sized studies.
In a previous paper of ours23, we described the methodology of the Italian Primary Open Angle Glaucoma 
Study (IPOAGS) and the baseline characteristics of the participants. In addition, that paper reported the 
association between vision-related QoL assessed with the 25-item National Eye Institute Visual Function 
Questionnaire (NEI-VFQ-25) and glaucoma-related symptoms assessed with the Glaucoma Symptoms Scale 
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(GSS) questionnaire23. It also presented the association between the NEI-VFQ-25 and GSS scores with glaucoma 
severity in a sample of 3169 patients23. In the current paper, our analysis was primarily focused on the impact of 
glaucoma (in terms of vision-related QoL and glaucoma-related symptoms) according to the number of perimet-
rically affected eyes. Therefore, the aim of the current report is to describe the characteristics of IPOAGS patients 
who have no-, one-, or both eyes with visual field loss, and examine the association between the number of peri-
metrically affected eyes and NEI-VFQ-25 and GSS scores.
Patients and Methods
Details regarding the multicenter IPOAGS study have been described elsewhere23. Briefly, twenty-one academic 
and non-academic Italian institutions were involved in the recruitment. Patients aged >18 years with a previous 
or new diagnosis (or strong clinical suspicion) of POAG were invited to participate during regular visits and 
were consecutively enrolled. Patients were considered eligible for inclusion if they had optic nerve head damage 
typical for glaucoma, i.e. focal and/or generalized neuroretinal rim thinning or cup/disc ratio asymmetry >0.2 in 
the absence of other neurodegenerative diseases. The presence of characteristic glaucomatous visual field defects 
was not a prerequisite for inclusion. Women who were pregnant, breast-feeding or had plans to become pregnant 
were excluded. Other exclusion criteria were the concurrent abuse of alcohol or illicit substances, and the partic-
ipation in any clinical trial that tested medications or medical devices within 30 days prior to recruitment. The 
validated Italian version of the NEI-VFQ-25 was used for the assessment of vision-related QoL24. The validated 
Italian version of the GSS Questionnaire25 was used for the assessment of glaucoma-related visual and non-visual 
symptoms.
The NEI-VFQ-25 is a self-administered 25-item, 12-subscale questionnaire assessing the following: gen-
eral health, general vision, ocular pain, near activities, distant activities, social functioning, mental health, role 
difficulties, dependency, driving, color vision, and peripheral vision26–28. The scoring procedure converts the 
pre-coded numeric values of each item to a score ranging from 0 to 100. Higher scores reflect better vision-related 
QoL. The global score is the mean score of all items that constitute 11 of the 12 subscales, with the exception of the 
single item that constitutes the general-health subscale.
The GSS Questionnaire29, a glaucoma specific tool, is a modified version of a checklist of symptoms devel-
oped by the Ocular Hypertension Treatment Study group. The tool includes 10 items grouped into two domains: 
Symp-6 for non-visual symptoms (burning/smarting/stinging, tearing, dryness, itching, soreness/tiredness, feel-
ing of something in the eye) and Func-4 for visual symptoms (blurry/dim vision, hard to see in daylight, hard 
to see in darkness, and halos around lights). The ten items assess each eye separately using a scale from 0 to 100, 
where zero indicates the presence of a very bothersome symptom and 100 the absence of the symptom. The 
domain score is the un-weighted average of the scores of the items that make up the domain in question. Similarly, 
the total GSS score is the mean of the 10 item scores. GSS scores can be calculated as average of the two eyes and 
for each eye separately.
The severity of VF damage was classified according to the Glaucoma Staging System 230–32. The Glaucoma 
Staging System 2 is a classification method31 that uses Mean Defect or Mean Deviation (MD) and Pattern 
Standard Deviation/Corrected Pattern Standard Deviation (PSD/CPSD) or Loss Variance/Corrected Loss 
Variance (LV/CLV) values (from either the 30-2/24-2 Zeiss-Humphrey tests or the G1/G1X/G2 Octopus pro-
grams) on a Cartesian coordinate diagram. The visual fields are divided in seven different stages by curvilinear 
lines from stage 0 (normal visual fields) through borderline to stage 5 (low threshold readings, with only small 
remnants of sensitivity remaining). This nomogram allows the user to quickly determine the stage of the dis-
ease (Fig. 1). When compared to other VF staging systems (e.g. The Advanced Glaucoma Intervention Study 
scoring system33 or the Hodapp-Anderson-Parrish system34), the Glaucoma Staging System 2 has been demon-
strated to be preferable for its ease of use for clinicians and researchers alike35. Furthermore, it has been used in 
population-based studies and clinical trials36–40.
Based on the presence of glaucoma and perimetric damage, eyes were classified in three categories: a) eyes 
without signs of glaucoma (WOG), i.e. fellow eyes of patients with unilateral glaucoma; b) eyes with glaucoma 
but no VF damage (WOD), i.e. “pre-perimetric” glaucoma: VF stage 0-borderline; c) eyes with glaucoma and VF 
damage (WD; VF stage 1 or greater). Participants, on the other hand, were classified in three categories: patients 
without VF damage in any eye (VFD-0), patients with VF damage in one eye (VFD-1), and patients with VF 
damage in both eyes (VFD-2). Two analyses were performed, one considering patients as units of analysis, and 
one considering eyes as units of analysis.
Descriptive summary statistics are presented as mean, standard deviation, minimum and maximum values 
for continuous variables, and as absolute frequency and percentage for categorical variables. The Chi-square 
test for trend and linear regression were used to investigate associations between VF and clinical character-
istics. When considering patients as units of analysis a linear regression model was fitted to test the effect of 
number of eyes with VF damage on questionnaires scores (performed with a generalized linear model proce-
dure). For each subscale, as well as for the total score of both the NEI-VFQ-25 and the GSS questionnaires, 
a multivariate model was fitted with the following covariates: age, best corrected visual acuity (BCVA, mean 
of the two eyes), previous treatment (treated versus untreated) and number of eyes with VF damage (VFD-0, 
VFD-1, VFD-2). VFD-0 was chosen as reference group for the latter variable; therefore p-values for VFD-1 and 
VFD-2 refer to the comparison of these groups versus VFD-0. For the “previous treatment” variable, untreated 
previously diagnosed or newly diagnosed patients were considered “untreated”, while previously diagnosed 
patients who had received medical and/or surgical treatment (or were currently under medical treatment) were 
considered “treated”.
When considering eyes as units of analysis, since we had to consider more than one measurement on the 
same subject (VF stage according to the Glaucoma Staging System 2, BCVA, MD, PSD, GSS questionnaire score), 
we needed to consider the correlation between these variables on the same subject. This analysis was performed 
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with a mixed model in order to take into account the correlation between eyes of the same subject (performed 
with mixed procedure). In our analysis the covariance structure hypothesized was the unstructured matrix. 
“Unstructured” means that no constraints were imposed on the values of covariance and variance. Therefore, 
the model estimates these quantities. Because there are about 6000 observations in our analysis, our study had 
the statistical power necessary to estimate the covariance structure from the data without compromising the 
efficiency of the model.
Figure 1. Visual field stages according to Glaucoma Staging System 2: simulation of what patients see at 
different stages. On the left Glaucoma Staging System 2 diagrams, in the middle visual field gray scale, on the 
right simulation of what patients see.
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Two multivariate analyses were performed to test the effect of presence and stage of VF damage at eye level on 
GSS questionnaire scores: the covariates of the first analysis included eye groups according to presence of glau-
coma and VF damage (WOG, WOD, WD), age, BCVA and previous treatment (treated versus untreated). The 
covariates of the second analysis included VF stage (according to the Glaucoma Staging System 2), age and BCVA. 
All analyses were performed with the SAS software (version 9.2).
The study was conducted in accordance with the tenets of the Declaration of Helsinki and the Guidelines for 
Good Clinical Practice. The ethic committee of Brescia (Comitato Etico provinciale di Brescia), and of each par-
ticipating centre approved the protocol (see list of Membership of the Italian Study Group on QoL in Glaucoma 
and participating centers). For inclusion, patients had to provide informed consent after the nature and purpose 
of the survey were fully explained. The study was registered with clinicaltrials.gov (NCT01742104).
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable 
request.
Results
From March 2012 to July 2013, 3227 patients were enrolled in 21 centers. Two hundred eighty seven patients were 
subsequently excluded due to incomplete filling of questionnaires (n = 58), incomplete data on staging (n = 47) 
or missing data on BCVA (n = 182). Consequently, 2940 patients were included in the per-eye analysis. As data 
on both eyes was not available for all patients, 2823 patients were included in the per-patient analysis. The demo-
graphic characteristics of the participants are presented in Table 1.
Patient as unit of analysis. Three hundred seventy eight patients (13.4%) were grouped as VFD-0, 669 
(23.7%) as VFD-1 and 1776 (62.9%) as VFD-2. Having more eyes with VF damage was associated with older 
age (p < 0.001) and worse BCVA (p < 0.001), but not with gender and race. Family history (p = 0.029), myopia 
(p = 0.012), diabetes (p < 0.001) and hypertension (p = 0.001) were all risk factors for having bilateral VF damage.
The percentage of patients using glaucoma medications was increasingly higher as the number of eyes with VF 
defects increased (91.6% for VFD-0 vs 93.5% for VFD-1 vs 94.8% for VFD-2, p = 0.017). Similarly, the percentage 
of patients using systemic concomitant treatments was increasingly higher as the number of eyes with VF defects 
increased (61.9% for VFD-0 vs 64.5% for VFD-1 vs 73.5% for VFD-2, p < 0.001) (Table 1).
Descriptive statistics for the GSS and NEI-VFQ-25 questionnaires are reported in Table 2. For the GSS ques-
tionnaire, the score of the visual symptoms domain (Func-4) for VFD-0 was similar to VFD-1 (adjusted mean 
difference (aMD) = −2.16 standard error (SE) = 1.44,p = 0.133), but significantly higher than VFD-2 patients 
(aMD = −8.30, SE = 1.30, p < 0.001) after adjusting for age, BCVA and previous treatment. The score of the 
non-visual symptoms domain (Symp-6) for VFD-0 was similar to VFD-1 (aMD = −0.29, SE = 1.36, p = 0.834), 
but higher than VFD-2 (aMD = −2.61, SE = 1.24, p = 0.035) after adjusting for age, BCVA and previous treat-
ment. Better BCVA and advanced age were associated with higher scores for both domains (BCVA: p < 0.001 
and p = 0.012 for Func-4 and Symp-6 respectively; age: p < 0.001 and 0.032 for Func-4 and Symp-6 respectively), 
while previous treatment was not associated with any score (p = 0.063 and p = 0.276 for Func-4 and Symp-6 
respectively). The same pattern was observed for the total score (Table 3).
Regarding the NEI-VFQ-25 questionnaire, our data indicate that bilateral VF defects are associated with 
vision-related QoL deterioration irrespective of BCVA (Table 4). Additionally, patients in the VFD-0 group 
had significantly higher vision-related QoL scores than patients in the VFD-1 group in the “General vision” 
(p = 0.029), “Driving” (p = 0.009) and “Peripheral vision” (0.013) subscales after adjusting for age, BCVA and 
previous treatment. In other words, even patients with VF defects in only one eye had significantly worse 
vision-related QoL scores in 3 of 12 subscales compared to patients without VF defects in any eye. Better BCVA 
was associated with higher scores for all subscales (p < 0.001 for all subscales). A similar pattern was observed for 
the total NEI-VFQ-25 score (Table 4).
Eye as unit of analysis. When considering eyes as units of analysis, 106 (1.9%) out of 5729 eyes were classi-
fied as WOG, 1304 (22.8%) as WOD and 4319 (75.4%) as WD.
Results of the GSS questionnaire based on presence of glaucoma and VF loss are depicted in Fig. 2. After 
adjusting for age, BCVA and previous treatment, not only glaucomatous eyes with VF defects (WD), but also 
glaucomatous eyes without VF defects (WOD) were associated with lower scores in the non-visual symptoms 
domain (Symp-6) compared to eyes without glaucoma (WOG) (p = 0.005 and p < 0.001 for WOD and WD 
respectively). For the visual symptoms domain (Func-4) only WD showed a lower score than eyes without glau-
coma (WOG) (p < 0.001), while no statistically significant difference was detected between WOD and WOG 
(p = 0.169) (Table 5). Better BCVA was associated with higher score for both domains and total score (p < 0.001). 
Age was statistically significant only for Symp-6 (p = 0.04), while previous treatment was only significant for 
Func-4 (p = 0.013).
The analysis of GSS results based on stage as determined with Glaucoma Staging System 2 is depicted in Fig. 3. 
Both in the non-visual symptoms domain (Symp-6) and in the visual symptoms domain (Func-4), a significant 
inverse relationship between VF stage and GSS score was seen after adjustment for age, BCVA and previous treat-
ment. The differences became statistically significant at stage 2, compared to stage 0. The same association was 
observed for total score (Table 6). Better BCVA was associated with higher score for both domains and total score. 
With the exception of the non-visual symptoms domain (Symp-6) (p = 0.025), age was not statistically significant. 
Previous treatment was statistically significant only for Func-4 (p = 0.025).
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Discussion
In the current study, being older was associated with a higher number of perimetrically affected eyes. A possible 
explanation for this association is that glaucoma is a chronic disease of the elderly, and the chances of perimetric 
defects appearing in one or both eyes increase with advancing age. Moreover, we found that factors such as family 
history, myopia, diabetes and systemic hypertension were associated with bilateral VF damage. These conditions 
have not consistently been demonstrated to be risk factors for the onset and progression of the disease41,42.
The proportion of patients using concomitant systemic treatments was higher for those with VF damage. 
Evidence has shown that systemic medications such as statins43,44, calcium channel blockers45 or diuretics46 have 
an influence on glaucoma risk. The exact effect of common systemic vasoactive medications on glaucoma risk 
remains to be determined. In the case of systemically administered β-blockers for instance, although this class 
of medications can have a protective effect in glaucoma because of a certain ocular hypotensive effect, the con-
current reduction in blood pressure may compromise optic nerve perfusion pressure47. In fact, evidence from 
population-based studies has shown that systemic hypotension may be associated with an increased prevalence 
and incidence of open-angle glaucoma48–50.
Deterioration of vision-related QoL has been reported even in patients with early VF loss21,22. In the Los 
Angeles Latino Eye Study for instance, adults with glaucoma experienced measurable loss in QoL early in the 
disease process22. Our data from a larger, ethnically different population are in accordance with those results: 
we found that patients with VF damage in one eye had lower vision-related QoL scores in three of twelve 
NEI-VFQ-25 subscales compared to patients without VF damage in any eye. There are several reasons for the 
VFD-0 (n = 378) VFD-1 (n = 689) VFD-2 (n = 1776) p-value
Age (years)
Mean (SD) 62.4 (11.4) 65.0 (11.8) 68.8 (11.7) <0.001*
Min-max 23.6–91.1 23.8–100.0 18.6–100.6
Male gender 186 (49.2) 338 (50.5) 876 (49.3) 0.863^
Race
Asian 0 (0.0) 2 (0.3) 3 (0.2) 0.876^
Black 1 (0.3) 4 (0.6) 9 (0.5)
Caucasian 377 (99.7) 663 (99.1) 1764 (99.3)
BCVA (Decimal fraction) [Snellen]
Mean (SD) 0.93 (0.1)[20/21.5 (20/200)] 0.87 (0.2) [20/23.0 (20/100)] 0.79 (0.2) [20/25.3 (20/100)] <0.001*
Min-max 0.04–1.0[20/500–20/20] 0.02–1.0[20/1000–20/20] 0.00–1.0 [0.0 –20/20]
Newly Diagnosed 20 (5.29) 39 (5.83) 108 (6.08) 0.557^
Previous treatment# <0.001^
None 22 (6.2) 21 (3.3) 27 (1.6)
Only medical 279 (77.9) 419 (66.5) 1194 (71.6)
Only surgical 8 (2.2) 20 (3.2) 60 (3.6)
Medical and surgical 49 (13.7) 170 (27.0) 386 (23.2)
Type of surgery (n = 693)
Trabeculectomy 21 (36.8) 95 (50.0) 268 (60.1) <0.001^
Viscocanalostomy 0 (0.0) 2 (1.1) 1 (0.2) 0.537^
Deep-sclerectomy 0 (0.0) 3 (1.6) 16 (3.6) 0.053^
Argon laser trabeculoplasty 40 (70.2) 117 (61.6) 205 (46.0) <0.001^
Glaucoma medication 328 (91.6) 589 (93.5) 1581 (94.8) 0.017^
β-blockers 93 (28.4) 152 (25.9) 364 (23.0) 0.025^
CAIs 22 (6.7) 57 (9.7) 214 (13.5) <0.001^
Prostaglandin analogues 167 (50.9) 275 (46.7) 830 (52.5) 0.163^
Parasympathomimetic drugs 5 (1.5) 28 (4.8) 53 (3.4) 0.456^
Prostaglandin + β-blocker FC 47 (14.3) 127 (21.6) 327 (20.7) 0.045^
Alpha agonist + β-blocker FC 10 (3.1) 30 (5.1) 72 (4.6) 0.432^
CAI + β-blocker FC 56 (17.1) 129 (21.9) 416 (26.3) <0.001^
Systemic treatment 234 (61.9) 430 (64.5) 1299 (73.5) <0.001^
Glaucoma family history 154 (40.7) 242 (36.2) 614 (34.6) 0.029^
Myopia 49 (13.0) 112 (16.7) 327 (18.4) 0.012^
Diabetes 40 (10.6) 75 (11.2) 287 (16.2) <0.001^
Hypertension 186 (49.2) 331 (49.5) 998 (56.2) 0.001^
Table 1. Characteristics of study subjects based on the number of eyes with visual field damage. Min, minimum 
value; max, maximum value; SD, standard deviation; BCVA, best corrected visual acuity; VFD-0, patients 
without visual field damage in any eye; VFD-1, patients with visual field damage in one eye; VFD-2, patients 
with visual field damage in both eyes; CAI, carbonic anhydrase inhibitor; FC, fixed combination; *, linear 
regression model; ^, chi square test for trend; #in patients not newly diagnosed.
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deterioration of QoL in early glaucoma. The most important is obviously related to the adverse effects, inconven-
ience and cost of antiglaucoma medications51–53. Another reason may be the psychological burden of suffering 
from a potentially blinding disease54. This psychological pressure may explain the observation that even the diag-
nosis of “glaucoma suspect” is associated with deterioration of vision-related QoL9,55,56. At least in theory, a third 
reason that could explain the deterioration of vision-related QoL even in perimetrically unaffected glaucomatous 
eyes is that certain aspects of visual function beyond retinal sensitivity, such as color perception, contrast sensi-
tivity and motion perception are affected early in the glaucomatous process57,58.
In our study, both visual and non-visual glaucoma-related symptoms were more bothersome with increas-
ing stage of perimetric damage. Of note, eyes with pre-perimetric glaucoma (or eyes suspicious for glaucoma) 
had worse score in the non-visual symptoms domain and worse total score at the GSS questionnaire than eyes 
without glaucoma. We believe that the worse symptom scores in these eyes are due to the use of anti-glaucoma 
medications.
In the present investigation, patients with glaucoma and VF damage in both eyes had significantly worse 
scores in both the non-visual and the visual symptom domains of the GSS tool compared to patients with-
out VF defects in any eye. The visual symptoms domain in particular showed good discrimination between 
patients with visual field defects in both eyes and patients without visual field defects in any eye. In patients 
with advanced glaucoma, the areas of VF defects in each eye may coincide, resulting in binocular VF loss59. 
Several studies have shown that patients with binocular VF loss experience severe difficulties in activities of 
daily life, such as reading, moving around or driving15–18. The location of VF defects may also play an impor-
tant role in the patients’ functioning and perception of vision-related QoL22. For example, Sawada et al.60 have 
shown that perimetric defects in the lower paracentral visual field of the better eye have the strongest correla-
tion with NEI-VFQ-25 scores. These authors also reported that defects in the upper temporal visual field have a 
strong impact on the driving subscale of the NEI-VFQ-25 questionnaire (r = 0.509, p < 0.001), while defects at 
the lower peripheral visual field strongly correlate with subscales such as role limitation (r = 0.459, p < 0.001) 
and peripheral vision (r = 0.425, p < 0.001)60. Other investigators have found that superior perimetric defects 
in binocular integrated visual fields are associated with difficulty with near activities, while inferior perimetric 
defects in binocular integrated visual fields are associated with vision-specific role difficulties, as well as general 
and peripheral vision61.
Our report provides evidence that VF loss is associated with decreased vision-related QoL in a manner that is 
independent of BCVA deterioration. To date, several studies have shown that visual acuity loss is one of the causes 
associated with lower vision-related QoL in glaucoma patients62–64.
The current study constitutes the largest investigation on vision-related QoL and glaucoma-related symp-
toms12,22,24,25,28,65–80. However, our sample cannot be considered representative in a strict methodological sense 
because it was not formed by means of random inclusion from a central nationwide registry. Since such a reg-
istry is not available, our sample can be considered as close as possible to being representative by virtue of its 
wide-ranging geographical distribution, recruitment from diverse academic and non-academic centers, and size.
VFD-0 VFD-1 VFD-2
Mean (SD) Mean (SD) Mean (SD)
GSS questionnaire
Func-4 84.0 (18.6) 80.5 (19.7) 73.0 (24.6)
Symp-6 76.1 (21.7) 75.6 (20.2) 73.2 (21.3)
Total score 79.4 (18.0) 77.6 (17.3) 73.1 (19.7)
NEI-VFQ-25
General health 60.88 (17.04) 58.77 (17.53) 55.25 (17.82)
General vision 68.06 (13.16) 64.31 (14.42) 58.05 (16.21)
Ocular pain 81.3 (18.6) 79.28 (18.57) 76.83 (20.72)
Near activities 90 (13.46) 86.41 (15.68) 79.97 (20.9)
Distance activities 94.74 (9.23) 91.48 (13.12) 85.88 (18.44)
Vision-specific social functioning 98.18 (6.94) 96.72 (9.61) 93.18 (14.52)
Vision-specific mental health 84.83 (14.09) 81.09 (17.65) 75.9 (21.35)
Vision-specific role difficulties 95.02 (12.41) 91.73 (15.64) 86.26 (21.05)
Vision-specific dependency 97.64 (8.91) 95.44 (13.88) 90.57 (20.14)
Driving 90.38 (14.49) 83.91 (20.99) 78.61 (25.26)
Color vision 98.67 (7.62) 96.95 (11.28) 93.82 (16.38)
Peripheral vision 94.69 (12.57) 89.46 (18.33) 83.7 (23.01)
Total score 90.27 (8.22) 87.00 (11.29) 82.03 (15.74)
Table 2. Glaucoma Symptom Scale (GSS) and National Eye Institute Visual Function (NEI-VFQ-25) 
questionnaire scores based on the number of eyes with visual field damage. SD, standard deviation; VFD-0, 
patients without visual field damage in any eye; VFD-1, patients with visual field damage in one eye; VFD-2, 
patients with visual field damage in both eyes; GSS, Glaucoma Symptom Scale; NEI-VFQ-25, National Eye 
Institute Visual Function Questionnaire-25.
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Intercept VFD-1 VFD-2 Age BCVA Previous treatment
β (Stderr) p-value β (Stderr) p-value* β (Stderr) p-value* β (Stderr) p-value β (Stderr) p-value β (Stderr) p-value
Func-4 54.24 (3.69) <0.001 −2.16 (1.44) 0.133 −8.3 (1.3) <0.001 0.13 (0.04) <0.001 25.75 (2.11) <0.001 −2.82 (1.52) 0.063
Symp-6 68.14 (3.51) <0.001 −0.29 (1.36) 0.834 −2.61 (1.24) 0.035 0.07 (0.03) 0.032 5.04 (2.01) 0.012 −1.57 (1.44) 0.276
Total score 62.58 (3.12) <0.001 −1.15 (1.21) 0.344 −4.97 (1.1) <0.001 0.1 (0.03) 0.001 13.32 (1.78) <0.001 −1.98 (1.28) 0.123
Table 3. Glaucoma Symptom Scale (GSS) questionnaire scores and number of eyes with visual field damage: 
statistical analysis (per-patient analysis). VFD-1, patients with visual field damage in one eye; VFD-2, patients 
with visual field damage in both eyes; BCVA, best corrected visual acuity; β, beta coefficient; SE, standard error 
for beta coefficient; p-value for multivariate linear regression model including visual field damage groups, 
BCVA, age, previous treatment (treated versus untreated); *, p-values for VFD-1 and VFD-2 refer to the 
comparison between each group and VFD-0 (patients without visual field damage in any eye).
Intercept VFD-1 VFD-2 Age BCVA Previous treatment
β (Stderr) p-value β (Stderr) p-value* β (Stderr) p-value* β (Stderr) p-value β (Stderr) p-value β (Stderr) p-value
General health 67.99 (2.91) <0.001 −1.25 (1.13) 0.268 −3.76 (1.02) <0.001 −0.16 (0.03) <0.001 5.59 (1.67) <0.001 −2.45 (1.20) 0.041
General vision 47.98 (2.42) <0.001 −2.06 (0.94) 0.029 −6.49 (0.85) <0.001 0 (0.02) 0.973 25.04 (1.39) <0.001 −3.53 (1.00) <0.001
Ocular pain 68.37 (3.29) <0.001 −1.36 (1.28) 0.289 −3.13 (1.16) 0.007 0.08 (0.03) 0.021 12.47 (1.89) <0.001 −3.81 (1.36) 0.005
Near activities 63.44 (2.97) <0.001 −1.59 (1.16) 0.170 −5.85 (1.05) <0.001 0 (0.03) 0.876 30.53 (1.7) <0.001 −2.36 (1.22) 0.054
Distance activities 69.37 (2.53) <0.001 −1.36 (0.99) 0.169 −4.84 (0.89) <0.001 −0.01 (0.03) 0.737 29.03 (1.45) <0.001 −1.21 (1.04) 0.244
Social functioning 82.18 (2.00) <0.001 −0.09 (0.78) 0.907 −2.12 (0.71) 0.003 −0.03 (0.02) 0.196 19.83 (1.15) <0.001 −0.94 (0.82) 0.255
Mental health 58.59 (3.14) <0.001 −2.08 (1.22) 0.088 −5.57 (1.11) <0.001 0.08 (0.03) 0.009 27.42 (1.8) <0.001 −4.9 (1.29) <0.001
Role difficulties 68.99 (2.98) <0.001 −1.32 (1.16) 0.257 −4.65 (1.05) <0.001 0.01 (0.03) 0.665 30.08 (1.71) <0.001 −3.07 (1.23) 0.012
Dependency 77.4 (2.8) <0.001 −0.4 (1.09) 0.714 −3.26 (0.99) 0.001 −0.05 (0.03) 0.104 25.8 (1.61) <0.001 −1.03 (1.15) 0.370
Driving 67.31 (4.23) <0.001 −4.1 (1.56) 0.009 −7.29 (1.42) <0.001 −0.08 (0.04) 0.043 32.7 (2.55) <0.001 −2.56 (1.76) 0.146
Color vision 85.18 (2.32) <0.001 −0.42 (0.9) 0.642 −2.12 (0.81) 0.009 −0.04 (0.02) 0.110 18.23 (1.33) <0.001 −1.3 (0.95) 0.172
Peripheral vision 68.79 (3.31) <0.001 −3.18 (1.29) 0.013 −6.7 (1.16) <0.001 0 (0.03) 0.971 30.93 (1.89) <0.001 −3.11 (1.36) 0.022
Total score 68.69 (2.16) <0.001 −1.58 (0.84) 0.060 −4.7 (0.76) <0.001 0 (0.02) 0.944 25.57 (1.24) <0.001 −2.56 (0.89) 0.004
Table 4. National Eye Institute Visual Function (NEI-VFQ-25) questionnaire scores and number of eyes with 
visual field damage: statistical analysis (per-patient analysis). SD, standard deviation; VFD-1, patients with 
visual field damage in one eye; VFD-2, patients with visual field damage in both eyes; BCVA, best corrected 
visual acuity; β, beta coefficient; SE, standard error for beta coefficient; p-value for multivariate linear regression 
model including visual field damage groups, BCVA, age, previous treatment (treated versus untreated); *, 
p-values for VFD-1 and VFD-2 refer to the comparison between each group and VFD-0 (patients without visual 
field damage in any eye).
Figure 2. Glaucoma Symptom Scale (GSS) questionnaire scores depending on the presence of glaucoma and 
visual field damage (eye as unit of analysis).
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Another limitation of our study is related to the use of the NEI-VFQ-25 questionnaire. Despite its wide-
spread adoption in QoL research, this tool is not free of drawbacks. Although traditional validation techniques 
have shown that the tool is valid and reliable for the evaluation of vision-specific QoL, some advanced statistical 
approaches have detected low precision at least for some of its items67,73,81,82. In general, the evaluation of QoL 
Func-4 Symp-6 Total score
β (Stderr) p-value β (Stderr) p-value β (Stderr) p-value
Intercept 69.55 (2.81) <0.001 66.89 (2.61) <0.001 67.9 (2.33) <0.001
WOD* −2.41 (1.75) 0.169 −4.84 (1.7) 0.005 −3.81 (1.47) 0.009
WD* −6 (1.71) <0.001 −6.59 (1.66) <0.001 −6.31 (1.43) <0.001
Age 0.02 (0.04) 0.555 0.07 (0.03) 0.040 0.05 (0.03) 0.100
BCVA 9.27 (0.77) <0.001 4.37 (0.74) <0.001 6.34 (0.64) <0.001
Previous treatment −3.89 (1.56) 0.013 −1.48 (1.44) 0.306 −2.34 (1.29) 0.070
Table 5. Glaucoma Symptom Scale (GSS) questionnaire scores and visual field damage: statistical analysis (per-
eye analysis). WOD, eyes with glaucoma but no visual field damage; WD, eyes with glaucoma and visual field 
damage (stage 1 or greater); BCVA, best corrected visual acuity; β, beta coefficient; SE, standard error for beta 
coefficient; p-value for multivariate mixed model including visual field damage groups, BCVA, age, previous 
treatment (treated versus untreated); *, p-values for WOD and WD refer to the comparison between each group 
and the WOG (eyes without signs of glaucoma).
Figure 3. Glaucoma Symptom Scale (GSS) questionnaire scores by stage according to Glaucoma Staging 
System 2 (eye as unit of analysis).
www.nature.com/scientificreports/
9SCIENTIFIC RepoRts |  (2018) 8:619  | DOI:10.1038/s41598-017-19113-z
using a questionnaire has some limitations. One of them is that QoL assessment is subjective, so that patients with 
similar disability may rate their QoL differently. Another inherent limitation of this type of investigations is that 
self-reported visual ability can be impaired, at least to some extent, by several ophthalmic and systemic comorbid-
ities and psychosocial constraints. Conceivably, even when VF indices such as MD are comparable, a multitude 
of diverse determinants such as spatial distribution and depth of VF scotomas or speed of VF deterioration may 
affect differently patients with dissimilar lifestyles and expectations83. A certain limitation of our eye-level analysis 
is that the “non-glaucomatous” eyes (WOG) were not eyes of healthy controls, but fellow eyes of patients with 
monocular glaucoma (or fellow eyes of patients with high suspicion for monocular glaucoma.
In conclusion, in the current study, having more eyes with VF damage was associated with older age and worse 
BCVA. Self-reported family history of glaucoma, myopia, diabetes mellitus and systemic hypertension were all 
associated with bilateral VF defects. The percentage of patients using glaucoma medications was increasingly higher 
as the number of eyes with VF defects increased. At the patient level analysis, participants with no VF defects in any 
eye or VF defects in one eye had significantly better scores in the glaucoma-related vision- and non-vision symptom 
scores of the GSS instrument compared to patients with bilateral VF defects after adjusting for age and BCVA. After 
adjusting for age and BCVA, patients without VF defects in any eye had significantly better NEI-VFQ-25 scores in 
3 of 12 subscales (“general vision”, “driving”, “peripheral vision”) compared to patients with VF defects in one eye, 
and better NEI-VFQ-25 scores in all subscales compared to patients with VF defects in both eyes. At the eye level 
analysis, after adjusting for age and BCVA, eyes without glaucoma had significantly better scores than eyes with 
glaucoma that had VF defects or eyes with glaucoma that did not have VF defects in both the visual and non-visual 
symptom domains of the GSS instrument. A significant inverse relationship between VF stage and both the visual 
and non-visual symptom scores of the GSS tool was seen after adjustment for age and BCVA.
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